Elanco Animal Health Stock Forecast, Price & News

-0.10 (-0.28 %)
(As of 06/24/2021 04:26 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume4.81 million shs
Average Volume3.83 million shs
Market Capitalization$16.55 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ELAN News and Ratings via Email

Sign-up to receive the latest news and ratings for Elanco Animal Health and its competitors with MarketBeat's FREE daily newsletter.

Elanco Animal Health logo

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.03 out of 5 stars

Medical Sector

72nd out of 2,105 stocks

Pharmaceutical Preparations Industry

33rd out of 832 stocks

Analyst Opinion: 2.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Elanco Animal Health (NYSE:ELAN) Frequently Asked Questions

Is Elanco Animal Health a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Elanco Animal Health stock.
View analyst ratings for Elanco Animal Health
or view top-rated stocks.

What stocks does MarketBeat like better than Elanco Animal Health?

Wall Street analysts have given Elanco Animal Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Elanco Animal Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Elanco Animal Health's next earnings date?

Elanco Animal Health is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Elanco Animal Health

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health Incorporated (NYSE:ELAN) released its quarterly earnings results on Thursday, May, 6th. The company reported $0.37 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.14. The business had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.16 billion. Elanco Animal Health had a negative net margin of 14.83% and a positive trailing twelve-month return on equity of 4.26%. The firm's quarterly revenue was up 88.8% on a year-over-year basis. During the same quarter last year, the business earned $0.13 earnings per share.
View Elanco Animal Health's earnings history

How has Elanco Animal Health's stock price been impacted by COVID-19 (Coronavirus)?

Elanco Animal Health's stock was trading at $23.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ELAN stock has increased by 47.5% and is now trading at $34.99.
View which stocks have been most impacted by COVID-19

What guidance has Elanco Animal Health issued on next quarter's earnings?

Elanco Animal Health updated its second quarter 2021 earnings guidance on Wednesday, June, 23rd. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $1.23 billion-1.26 billion, compared to the consensus revenue estimate of $1.23 billion.

What price target have analysts set for ELAN?

13 brokerages have issued 1 year target prices for Elanco Animal Health's stock. Their forecasts range from $19.00 to $42.00. On average, they expect Elanco Animal Health's share price to reach $33.14 in the next year. This suggests that the stock has a possible downside of 5.3%.
View analysts' price targets for Elanco Animal Health
or view top-rated stocks among Wall Street analysts.

Who are Elanco Animal Health's key executives?

Elanco Animal Health's management team includes the following people:
  • Mr. Jeffrey N. Simmons, Pres, CEO & Director (Age 54, Pay $2.1M)
  • Mr. Todd S. Young, Exec. VP of Corp. Governance and Strategy & CFO (Age 49, Pay $934.92k)
  • Mr. Aaron L. Schacht, Exec. VP of Innovation, Regulatory & Bus. Devel. (Age 53, Pay $955.32k)
  • Mr. James M. Meer, VP & Chief Accounting Officer (Age 51)
  • Mr. Chris Keeley, Sr. VP & Chief Information Officer
  • Mr. David S. Kinard, Exec. VP of HR Corp. Affairs & Admin. (Age 54)
  • Ms. Tiffany Ann Kanaga, Head of Investor Relations
  • Ms. Jinee Majors, Sr. Assistant Gen. Counsel & Assistant Corp. Sec.
  • Ms. Racquel Harris Mason, Exec. VP & Chief Marketing Officer (Age 51)
  • Mr. Ramiro Martin Cabral, Exec. VP of Elanco International (Age 49)

What is Jeff Simmons' approval rating as Elanco Animal Health's CEO?

169 employees have rated Elanco Animal Health CEO Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among Elanco Animal Health's employees.

Who are some of Elanco Animal Health's key competitors?

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), The Walt Disney (DIS), Johnson & Johnson (JNJ), AT&T (T), Cisco Systems (CSCO), CVS Health (CVS) and Bristol-Myers Squibb (BMY).

When did Elanco Animal Health IPO?

(ELAN) raised $1.4 billion in an initial public offering (IPO) on Thursday, September 20th 2018. The company issued 62,900,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

What is Elanco Animal Health's stock symbol?

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (8.83%), Primecap Management Co. CA (6.67%), BlackRock Inc. (6.22%), Janus Henderson Group PLC (5.95%), Amundi Asset Management US Inc. (2.77%) and Kayne Anderson Rudnick Investment Management LLC (1.97%). Company insiders that own Elanco Animal Health stock include Aktiengesellschaft Bayer, Art A Garcia, David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, Michael-Bryant Hicks, R David Hoover and Todd S Young.
View institutional ownership trends for Elanco Animal Health

Which institutional investors are selling Elanco Animal Health stock?

ELAN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Nomura Holdings Inc., Davidson Kempner Capital Management LP, Davidson Kempner Capital Management LP, Primecap Management Co. CA, Segantii Capital Management Ltd, Barclays PLC, and One Fin Capital Management LP.
View insider buying and selling activity for Elanco Animal Health
or view top insider-selling stocks.

Which institutional investors are buying Elanco Animal Health stock?

ELAN stock was acquired by a variety of institutional investors in the last quarter, including Starboard Value LP, Morgan Stanley, Canada Pension Plan Investment Board, Dendur Capital LP, BlackRock Inc., Maverick Capital Ltd., Amundi Asset Management US Inc., and Point72 Asset Management L.P.. Company insiders that have bought Elanco Animal Health stock in the last two years include Art A Garcia, David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, and Todd S Young.
View insider buying and selling activity for Elanco Animal Health
or or view top insider-buying stocks.

How do I buy shares of Elanco Animal Health?

Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Elanco Animal Health's stock price today?

One share of ELAN stock can currently be purchased for approximately $34.99.

How much money does Elanco Animal Health make?

Elanco Animal Health has a market capitalization of $16.55 billion and generates $3.27 billion in revenue each year. The company earns $-560,100,000.00 in net income (profit) each year or $0.47 on an earnings per share basis.

How many employees does Elanco Animal Health have?

Elanco Animal Health employs 10,200 workers across the globe.

What is Elanco Animal Health's official website?

The official website for Elanco Animal Health is www.elanco.com.

Where are Elanco Animal Health's headquarters?

Elanco Animal Health is headquartered at 2500 INNOVATION WAY, GREENFIELD IN, 46140.

How can I contact Elanco Animal Health?

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261 or via email at [email protected]

This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.